Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -172.84% | 17.22% | -237.73% | 48.85% | 1.78% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 397.54% | -53.91% | 613.65% | -195.65% | 850.00% |
| Change in Net Operating Assets | 4,085.00% | 103.48% | -38.22% | -173.37% | -63.25% |
| Cash from Operations | 18.18% | -43.38% | 34.86% | -51.44% | -1.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -10.66% | 39.60% | 5.61% | 58.37% | 47.17% |
| Issuance of Common Stock | -96.12% | -- | -100.00% | 23.35% | -15.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -99.08% | 203.64% | -43.89% | 58.51% | -0.97% |
| Foreign Exchange rate Adjustments | -- | 100.00% | -175.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.55% | 1,297.80% | -275.97% | 858.82% | -104.12% |